(Q81094942)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

The increasingly complex fourth hurdle for pharmaceuticals (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Joshua Cohen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Elly Stolk

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Maartje Niezen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

727-734

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17803332%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00019053-200725090-00002

5 January 2020

exact match

0 references

cites work

Is economic evaluation in touch with society's health values?

1 reference

12 December 2020

National Institute for Clinical Excellence and its value judgments

1 reference

12 December 2020

Patient access to pharmaceuticals: an international comparison

1 reference

12 December 2020

The drug budget silo mentality: the French case

1 reference

12 December 2020

Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries

1 reference

12 December 2020

AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan

1 reference

12 December 2020

Should Public Policy Seek To Control The Growth Of Health Care Spending?

1 reference

12 December 2020

Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996)

1 reference

12 December 2020

Comparing patient access to pharmaceuticals in the UK and US.

1 reference

12 December 2020

Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees

1 reference

12 December 2020

Health plan budget impact analysis for pimecrolimus.

1 reference

12 December 2020

The "health benefit basket" in the Netherlands

1 reference

12 December 2020

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle

1 reference

12 December 2020

The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit?

1 reference

12 December 2020

Evidence-based and value-based formulary guidelines

1 reference

12 December 2020

The HAART side of resource allocation.

1 reference

12 December 2020

Are pharmaceuticals cost-effective? A review of the evidence.

1 reference

12 December 2020

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

1 reference

12 December 2020

Rationalising rationing: economic and other considerations in the debate about funding of Viagra.

1 reference

12 December 2020

Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale

1 reference

12 December 2020

Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?

1 reference

12 December 2020

Challenges for the National Institute for Clinical Excellence.

1 reference

12 December 2020

Drugs for exceptionally rare diseases: do they deserve special status for funding?

1 reference

12 December 2020

Penny and pound wise: pharmacoeconomics from a governmental perspective

1 reference

12 December 2020

The relationship between technology availability and health care spending

1 reference

12 December 2020

National health spending in 2004: recent slowdown led by prescription drug spending

1 reference

12 December 2020

The drug budget silo mentality: the Dutch case

1 reference

12 December 2020

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

1 reference

12 December 2020

Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.

1 reference

12 December 2020

The use of economic evaluations in NHS decision-making: a review and empirical investigation

1 reference

12 December 2020

Incremental cost-effectiveness ratios (ICERs): the silence of the lambda

1 reference

12 December 2020